Here you will find press releases, an image bank and can subscribe to our releases. If you do not find what you are looking for, do not hesitate to contact us.
- InDex Pharmaceuticals Holding AB (publ) interim report January – September 201819 November 2018
- InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting06 November 2018
- InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million23 October 2018
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.Learn more